{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:28:47Z","timestamp":1790180927825,"version":"4.1.0"},"reference-count":54,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"RNS, Stichting tegen Kanker","award":["2021 13"],"award-info":[{"award-number":["2021 13"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The landscape of clinical trials aimed at targeting specific proteins has experienced significant advancements, presenting promising opportunities for the development of effective therapeutics across a range of diseases. These trials focus on the investigation of modulation of protein functions, utilizing innovative technologies such as PROTACs (Proteolysis-Targeting Chimeras) and other protein degraders. These innovative approaches aim to address previously undruggable targets, enhancing the specificity and efficacy of treatments. The current landscape of clinical trials encompasses a diverse array of therapeutic areas, including oncology, autoimmune diseases, and neurological disorders. For instance, drugs like ARV-471 and ARV-110 are in advanced phases for treating metastatic breast cancer and prostate cancer, respectively, by targeting estrogen and androgen receptors. Early-phase trials explored the potential of targeting proteins like IKZF1\/3 in multiple myeloma and IRAK4 in autoimmune diseases. The conducted trials not only emphasize the therapeutic potential of protein degradation but also highlight the challenges associated with bioavailability, stability, and delivery mechanisms. As these clinical trials advance, they possess the potential to transform treatment paradigms, providing renewed hope for patients facing complex and refractory conditions.<\/jats:p>","DOI":"10.3390\/pharmaceutics17060744","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T11:04:06Z","timestamp":1749121446000},"page":"744","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Molecular Design of Novel Protein-Degrading Therapeutics Agents Currently in Clinical Trial"],"prefix":"10.3390","volume":"17","author":[{"given":"Ela","family":"Kacin","sequence":"first","affiliation":[{"name":"VIB-KU Leuven Center for Cancer Biology (VIB), 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9238-3242","authenticated-orcid":false,"given":"Raj Nayan","family":"Sewduth","sequence":"additional","affiliation":[{"name":"VIB-KU Leuven Center for Cancer Biology (VIB), 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs)\u2014Past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug. Discov. Today Technol."},{"key":"ref_2","first-page":"706","article-title":"A new path to targeted protein degradation?","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4\/6 or PI3K\/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_4","unstructured":"Biochempeg (2025, May 15). Comprehensive Overview of PROTACs in Development. Available online: https:\/\/www.biochempeg.com\/article\/289.html."},{"key":"ref_5","unstructured":"CAS (2025, May 15). Insights on PROTAC Drug Development: Current Progress and Future Directions. Available online: https:\/\/www.cas.org\/resources\/cas-insights\/protac-drug-development."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/s41591-023-02635-7","article-title":"IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: A phase 1 trial","volume":"29","author":"Ackerman","year":"2023","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Montoya, S., Bourcier, J., Noviski, M., Lu, H., Thompson, M.C., Chirino, A., Jahn, J., Sondhi, A.K., Gajewski, S., and Tan, Y.S.M. (2024). Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127. Science, 383.","DOI":"10.1126\/science.adi5798"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10548","DOI":"10.1021\/acs.jmedchem.3c01823","article-title":"Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma","volume":"67","author":"Weiss","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Jackson, K.L., Agafonov, R.V., Carlson, M.W., Chaturvedi, P., Cocozziello, D., Cole, K., Deibler, R., Scott, J., Good, E.A., and Hart, A.A. (2022). Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers. Cancer Res., 82.","DOI":"10.1158\/1538-7445.AM2022-ND09"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1038\/s41467-021-27210-x","article-title":"Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity","volume":"12","author":"Lv","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Guedeney, N., Cornu, M., Schwalen, F., Kieffer, C., and Voisin-Chiret, A.S. (2023). PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery. Drug. Discov. Today, 28.","DOI":"10.1016\/j.drudis.2022.103395"},{"key":"ref_12","unstructured":"Biochempeg (2025, May 15). Summary of PROTAC Degraders in Clinical Trials. Available online: https:\/\/www.biochempeg.com\/article\/282.html."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hyun, S., and Shin, D. (2021). Chemical-Mediated Targeted Protein Degradation in Neurodegenerative Diseases. Life, 11.","DOI":"10.3390\/life11070607"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhu, Y., Dai, Y., and Tian, Y. (2025). The Peptide PROTAC Modality: A New Strategy for Drug Discovery. MedComm, 6.","DOI":"10.1002\/mco2.70133"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4155\/fmc-2021-0206","article-title":"Designing HDAC-PROTACs: Lessons learned so far","volume":"14","author":"Fischer","year":"2022","journal-title":"Future Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: Expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/17460441.2023.2187777","article-title":"Novel approaches to targeted protein degradation technologies in drug discovery","volume":"18","author":"Xue","year":"2023","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1021\/acs.jmedchem.4c01017","article-title":"Structural and Physicochemical Features of Oral PROTACs","volume":"67","author":"Schade","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/2472555220965528","article-title":"E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones","volume":"26","author":"Ishida","year":"2021","journal-title":"SLAS Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1039\/D4MD00760C","article-title":"Expanding the reaction toolbox for nanoscale direct-to-biology PROTAC synthesis and biological evaluation","volume":"16","author":"Stevens","year":"2025","journal-title":"RSC Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.4155\/fmc-2021-0033","article-title":"Perspectives on the development of first-in-class protein degraders","volume":"13","author":"Rambacher","year":"2021","journal-title":"Future Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"117370","DOI":"10.1016\/j.ejmech.2025.117370","article-title":"An updated review on the role of small molecules in mediating protein degradation","volume":"287","author":"Wu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Tashima, T. (2023). Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier. Antibodies, 12.","DOI":"10.3390\/antib12030043"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/bs.mie.2023.06.020","article-title":"Methods for computer-assisted PROTAC design","volume":"690","author":"Rovers","year":"2023","journal-title":"Methods Enzym."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"VanDyke, D., Taylor, J.D., Kaeo, K.J., Hunt, J., and Spangler, J.B. (2022). Biologics-based degraders\u2014An expanding toolkit for targeted-protein degradation. Curr. Opin. Biotechnol., 78.","DOI":"10.1016\/j.copbio.2022.102807"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation: From mechanisms to clinic","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"112981","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13045-023-01398-5","article-title":"Protein degradation: Expanding the toolbox to restrain cancer drug resistance","volume":"16","author":"Ming","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Li, S., Chen, T., Liu, J., Zhang, H., Li, J., Wang, Z., and Shang, G. (2023). PROTACs: Novel tools for improving immunotherapy in cancer. Cancer Lett., 560.","DOI":"10.1016\/j.canlet.2023.216128"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: Past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_31","first-page":"32","article-title":"Targeted Protein Degradation for Infectious Diseases: From Basic Biology to Drug Discovery","volume":"3","author":"Salerno","year":"2022","journal-title":"ACS Bio Med. Chem. Au."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41586-024-07224-3","article-title":"Proteome-scale discovery of protein degradation and stabilization effectors","volume":"628","author":"Poirson","year":"2024","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.chembiol.2019.10.002","article-title":"From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9","volume":"27","author":"Petrilli","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Venkatesan, J., Murugan, D., Lakshminarayanan, K., Smith, A.R., Vasanthakumari Thirumalaiswamy, H., Kandhasamy, H., Zender, B., Zheng, G., and Rangasamy, L. (2024). Powering up targeted protein degradation through active and passive tumour-targeting strategies: Current and future scopes. Pharmacol. Ther., 263.","DOI":"10.1016\/j.pharmthera.2024.108725"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/17576180.2025.2481021","article-title":"Conquering PROTAC molecular design and drugability","volume":"17","author":"Bhole","year":"2025","journal-title":"Bioanalysis"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kim, H., Park, J., and Kim, J.M. (2022). Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway. Biomedicines, 10.","DOI":"10.3390\/biomedicines10092100"},{"key":"ref_37","unstructured":"Arvinas (2025, May 15). Phase 2 Data for ARV-110 in Prostate Cancer. ASCO Annual Meeting Abstracts. [Abstract #4505]. Journal Article Corresponding to a Meeting Abstract. Available online: https:\/\/meetings.asco.org\/abstracts-presentations\/169992."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1002\/cmdc.202100393","article-title":"LYTACs: An Emerging Tool for the Degradation of Non-Cytosolic Proteins","volume":"16","author":"Ramadas","year":"2021","journal-title":"Chem. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","article-title":"Protac-induced protein degradation in drug discovery: Breaking the rules or just making new ones?","volume":"61","author":"Churcher","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","article-title":"The rise of molecular glues","volume":"184","author":"Schreiber","year":"2021","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-019-0362-y","article-title":"Development of targeted protein degradation therapeutics","volume":"15","author":"Chamberlain","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: Cargo-specific degraders using selective autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1080\/15548627.2022.2091338","article-title":"Targeted protein degradation via the autophagy-lysosome system: AUTOTAC (AUTOphagy-TArgeting Chimera)","volume":"18","author":"Ji","year":"2022","journal-title":"Autophagy"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Danishuddin, Jamal, M.S., Song, K.S., Lee, K.W., Kim, J.J., and Park, Y.M. (2023). Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development. Pharmaceuticals, 16.","DOI":"10.3390\/ph16121649"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Abbas, A., and Ye, F. (2024). Computational methods and key considerations for in silico design of proteolysis targeting chimera (PROTACs). Int. J. Biol. Macromol., 277.","DOI":"10.1016\/j.ijbiomac.2024.134293"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.tips.2024.10.006","article-title":"Development of PROTACs using computational approaches","volume":"45","author":"Ge","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: Great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nchembio.2538","article-title":"Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation","volume":"14","author":"Olson","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"ref_54","first-page":"6649","article-title":"Discovery of ARD-69 as a highly potent PROTAC degrader of androgen receptor for prostate cancer","volume":"63","author":"Han","year":"2020","journal-title":"J. Med. Chem."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/6\/744\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:47:18Z","timestamp":1760032038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/6\/744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":54,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["pharmaceutics17060744"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17060744","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]}}}